Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Inventiva
  6. Company
    IVA   FR0013233012

INVENTIVA

(IVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Inventiva
Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

Number of employees : 94 people.
Sales per Business
20192020Delta
Oral Small Molecule Therapies4.7868.3%5.261414.8% +10.15%
EUR in Million
Sales per region
2020
France5.261414.8%
EUR in Million
Managers
Name Title Age Since
Frédéric Cren Chairman & Chief Executive Officer 54 2016
Jean Volatier Chief Financial & Administrative Officer 55 -
Pierre Broqua, Dr. Director, Deputy CEO & Chief Scientific Officer 58 2016
Michael P. Cooreman, Dr. Chief Medical Officer 62 2020
Chris Buyse Independent Director 55 -
Annick Schwebig, Dr. Independent Director 70 -
Lucy Lu, Dr. Independent Director 45 2018
Christoph Mäusli Heinz Independent Director 57 2019
Martine Zimmermann Independent Director - 2021
Kristina Meyer, Dr. Head-Business Development - -
Members of the board
Name Title Age Since
Frédéric Cren Chairman & Chief Executive Officer 54 2016
Pierre Broqua, Dr. Director, Deputy CEO & Chief Scientific Officer 58 2016
Chris Buyse Independent Director 55 -
Annick Schwebig, Dr. Independent Director 70 -
Lucy Lu, Dr. Independent Director 45 2018
Christoph Mäusli Heinz Independent Director 57 2019
Martine Zimmermann Independent Director - 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 38,630,261 28,069,194 72.7% 0 0.0% 72.7%
Shareholders
NameEquities%
BVF Partners LP 7,958,138 20.7%
Frédéric Cren 5,612,224 14.6%
NEA Management Co. LLC 5,152,033 13.4%
Pierre Broqua 3,882,500 10.1%
Sofinnova Partners SAS 3,114,027 8.11%
Polar Capital LLP 1,000,000 2.60%
Candriam Belgium SA 680,000 1.77%
Medical Strategy GmbH 192,757 0.50%
DWS Investment GmbH 129,411 0.34%
Isls Consulting SARL 111,000 0.29%
Holdings
NameEquities%Valuation
INVENTIVA (IVA) 24,237 0.063% 333,990 USD
Markets and indexes
- PEA / SRD eligible : YES / YES
- Compartiment B
- CAC Small / CAC All Shares, CAC All-Tradable, CAC Mid Small, CAC PME, EnterNext© PEA-PME 150, Next Biotech, PEA, PEA-PME
Stock Exchange Codes
- Bloomberg Code :  IVA:FR
- Reuters Code :  IVA.PA
- Datastream Code :  
Company contact information
Inventiva
50 Rue de Dijon
FR-21121 Daix

Phone : +33 (0)3 80 44 75 00
Fax :
web site : http://www.inventivapharma.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Inventiva
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
INVENTIVA-2.22%525
GILEAD SCIENCES, INC.19.86%87 579
BIONTECH SE302.78%75 497
WUXI APPTEC CO., LTD.33.61%70 844
REGENERON PHARMACEUTICALS20.70%60 387
VERTEX PHARMACEUTICALS-14.71%51 872
GENMAB A/S13.80%29 283
BEIGENE, LTD.22.52%28 945
ARGENX SE6.32%15 501
HUALAN BIOLOGICAL ENGINEERING INC.-12.90%10 396
NEUROCRINE BIOSCIENCES, INC.-2.75%8 785
MIRATI THERAPEUTICS, INC.-27.22%8 223
FATE THERAPEUTICS, INC.-8.94%8 091
ACCELERON PHARMA INC.-2.25%7 708
ARROWHEAD PHARMACEUTICALS, INC.-10.96%7 111
GW PHARMACEUTICALS PLC89.72%6 907
REMEGEN CO., LTD.4.47%6 391
LEGEND BIOTECH CORPORATION52.81%6 354
ASCENDIS PHARMA A/S-29.13%6 293
DENALI THERAPEUTICS INC.-39.12%6 180
BIOCON LIMITED-17.80%6 128